Please login to the form below
NHS Scotland
This page shows the latest NHS Scotland news and features for those working in and with pharma, biotech and healthcare.
NHS Scotland to offer Jyseleca for patients with moderate rheumatoid arthritis
NHS Scotland will now be able to offer Galapagos Biotech’s Jyseleca (filgotinib) to patients with moderate rheumatoid arthritis (RA), following a recommendation from the Scottish Medicines Consortium (SMC). ... We are delighted that people living with
Latest news
-
Janssen’s Erleada combination accepted in Scotland for prostate cancer
been accepted by the Scottish Medicines Consortium (SMC) as an option for treating adults with metastatic hormone-sensitive prostate cancer (mHSPC) within NHS Scotland. ... The acceptance of [Erleada] for use in NHS Scotland adds another effective and
-
NHS awarded George Cross for efforts shown during the COVID-19 pandemic
The NHS has been awarded the George Cross by Her Majesty The Queen in recognition of the dedicated service of healthcare workers that includes their ‘courage, compassion and dedication’ during the ... The pair were joined by Pritchard’s counterparts
-
NICE issues final appraisal recommending LEO Pharma’s Adtralza for moderate-to-severe atopic dermatitis
The decision from NICE follows a multiple technology appraisal (MTA) and its recommendation simultaneously approves Adtralza, Rinvoq (upadacitinib) and Cibinqo (abrocitinib) for reimbursement following use in NHS England and Wales, which ... In January
-
Seagen’s Tukysa granted NICE recommendation for breast cancer patients
The combination treatment includes Tukysa combined with an intravenous infusion of trastuzumab and capecitabine and is now available for routine funding on the NHS in England and Wales, with around 400 ... NICE’s decision follows the Scottish Medicines
-
SMC approves Parkinson’s disease treatment Ongentys
The once-daily additional oral treatment for patients living with Parkinson’s disease is now accepted for use within NHS Scotland. ... Bial has announced that its treatment Ongentys (opicapone) has been accepted for use within NHS Scotland after a
More from news
Approximately 5 fully matching, plus 57 partially matching documents found.
Latest Intelligence
-
Getting below the surface: regional and local market access
In the UK, NHS England, NHS Scotland and NHS Wales make decisions at national levels over specialised commissioning.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
ABPI Scotland appoints Sandra Auld as director
She will spearhead the ABPI Scotland team, working closely with the Scottish Government and NHS Scotland. ... Auld added: “I am absolutely delighted to become the Director of ABPI Scotland.
-
Scottish cabinet reshuffle sees Alex Neil made health secretary
Sturgeon's work was also praised by Scotland's First Minister Alex Salmond: “She delivered record low waiting times and protected the NHS [in Scotland] from the creeping privatisation of the ... He enters his new role at a 'difficult and interesting
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
Adelphi Grows Team
RJ is highly experienced in both qualitative and quantitative methodologies and has worked with a range of organisations including NHS Scotland.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Europe’s cancer community publishes new report on transforming patient care
- Eli Lilly announces $450m investment in US manufacturing site
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- ASH 2022: bad blood but big advances
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- MIT researchers develop AI model to detect future lung cancer risk
- GSK’s Benlysta given orphan drug status by FDA for systemic sclerosis
- Kite and Arcellx close multiple myeloma collaboration agreement
- The challenges of identifying rare diseases
- Live Webinar: Streamlining Healthcare Delivery Through Digital Care Journeys
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- Boehringer reports positive phase 2 data for spesolimab in generalised pustular psoriasis
- EU outlines measures to mitigate antibiotic shortage across Europe
- The challenges of identifying rare diseases
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- This month in 1917: A tale of two Mercks
PMHub
Cuttsy + Cuttsy
Here at Cuttsy+Cuttsy, we believe in making the world a better place by bringing trusted, accessible information to all and...
Latest intelligence
- The challenges of identifying rare diseases
- With increased awareness and improved diagnosis, more rare diseases are being recognised and this number is likely to increase in the coming years...
- 5 ways we’re enhancing our services to support our clients in 2023
- Fishawack Health CEO Jon Koch explains the new platforms, tools, and services we’re elevating to drive innovation for our clients in 2023....
- ASH 2022: bad blood but big advances
- Five trends from this year’s ASH conference – and why even pop icons can’t compete with the playlist of innovation shaping haematology...
